title: Surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas.
abstract: BACKGROUND
  Recurrent abdominal sarcomas have an extremely high rate of recurrence and poor overall survival. A prospective study was initiated to assess the feasibility, toxicity, and benefit of surgical resection and intraperitoneal chemotherapy for improving local control of disease and overall survival.
  
  
  METHODS
  Fifty-four patients underwent surgical excision of all gross disease and postoperative intraperitoneal chemotherapy with mitoxantrone. Thirty-five patients had peritoneal disease only (stage II), and 19 patients had peritoneal disease with hepatic metastases (stage III).
  
  
  RESULTS
  Nine (17%) patients remain free of disease with a mean follow-up of 37 months. The remaining 45 patients (83%) have had recurrence, with a mean interval to recurrence of 11 months. Stage (P = .001) and grade (P = .005) were the only two variables found to significantly affect recurrence. There was an overall peritoneal recurrence rate of 48% and an overall hepatic failure rate of 69%. Nineteen (35%) of the patients are alive, with a mean follow-up of 46 months. The overall 5-year survival was 31%. The 5-year survival for stage II patients was 46%; for stage III patients, it was only 5%. Stage (P = .001) and grade (P = .056) were the only two variables found to significantly affect survival. There were no treatment-related deaths, and only 5 patients (9%) developed local complications.
  
  
  CONCLUSIONS
  Aggressive surgical resection and intraperitoneal chemotherapy for recurrent abdominal sarcomas is a feasible treatment approach with minimal toxicity. Although this treatment had little effect on the hepatic spread of this disease and thus overall survival, it appears to have significantly lowered the rate of peritoneal recurrence and may provide a survival benefit for patients with disease limited to the peritoneum.
authors.affiliation: Division of Surgical Oncology, UCLA Musculo-Skeletal Study Group, University of California, Los Angeles 90095, USA.
authors.forename: F C
authors.initials: FC
authors.lastname: Eilber
authors.forename: G
authors.initials: G
authors.lastname: Rosen
authors.forename: C
authors.initials: C
authors.lastname: Forscher
authors.forename: S D
authors.initials: SD
authors.lastname: Nelson
authors.forename: F J
authors.initials: FJ
authors.lastname: Dorey
authors.forename: F R
authors.initials: FR
authors.lastname: Eilber
mesh_terms: D000008:Abdominal Neoplasms / Q000188:drug therapy* / Q000601:surgery*; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D003131:Combined Modality Therapy; D005240:Feasibility Studies; D005260:Female; D006801:Humans; D007263:Infusions, Parenteral; D008113:Liver Neoplasms / Q000473:pathology / Q000556:secondary; D008297:Male; D008875:Middle Aged; D008942:Mitoxantrone / Q000627:therapeutic use*; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000601:surgery*; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012509:Sarcoma / Q000188:drug therapy* / Q000601:surgery*; D016019:Survival Analysis
chemical_list: D000970:Antineoplastic Agents; D008942:Mitoxantrone